BCMED: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
BCMED
Largest movements
- Cash -€5,803
down €5,803 (-87.6%), from €6,622 to €819
mainly Receivables within one year (-€5,307) and Net result for the year (-€2,686)
- Receivables within one year +€5,307
up €5,307 (+125.8%), from €4,219 to €9,526
of which Trade receivables: +€5,822
- Deferred charges and accrued income +€1,009
up €1,009 (+2690.3%), from €38 to €1,047
- Profit (loss) carried forward -€4,352
down €4,352 (-79.7%), from €5,458 to €1,107
- Trade debts +€2,518
up €2,518 (+2442.8%), from €103 to €2,621
- Other debts +€1,228
up €1,228 (+100.5%), from €1,222 to €2,449
- Accrued charges and deferred income +€1,119
new in 2024: €1,119
- Gross operating margin -€17,596
down €17,596, from €16,909 to -€687
- Staff costs -€5,926
down €5,926 (-82.5%), from €7,182 to €1,257
- Taxes -€2,595
down €2,595 (-100.0%), from €2,595 to €0
- Other operating charges +€808
new in 2024: €808
From the 2023 result to the 2024 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2023 and 2024 balance sheets and the 2024 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €10,878 | €11,391 | +€513 | +4.7% |
| Current assets | 29/58 | €10,878 | €11,391 | +€513 | +4.7% |
| Amounts receivable within one year | 40/41 | €4,219 | €9,526 | +€5,307 | +125.8% |
| Trade receivables | 40 | €1,172 | €6,994 | +€5,822 | +496.9% |
| Other amounts receivable | 41 | €3,047 | €2,532 | -€515 | -16.9% |
| Cash at bank and in hand | 54/58 | €6,622 | €819 | -€5,803 | -87.6% |
| Deferred charges and accrued income | 490/1 | €38 | €1,047 | +€1,009 | +2690.3% |
| Total equity and liabilities | 10/49 | €10,878 | €11,391 | +€513 | +4.7% |
| Equity | 10/15 | €6,458 | €2,107 | -€4,352 | -67.4% |
| Contributions | 10/11 | €1,000 | €1,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €5,458 | €1,107 | -€4,352 | -79.7% |
| Amounts payable | 17/49 | €4,419 | €9,285 | +€4,865 | +110.1% |
| Amounts payable within one year | 42/48 | €4,419 | €8,165 | +€3,746 | +84.8% |
| Trade debts | 44 | €103 | €2,621 | +€2,518 | +2442.8% |
| Suppliers | 440/4 | €103 | €2,621 | +€2,518 | +2442.8% |
| Taxes, remuneration and social security | 45 | €3,095 | €3,095 | = | 0.0% |
| Taxes | 450/3 | €3,095 | €3,095 | = | 0.0% |
| Other amounts payable | 47/48 | €1,222 | €2,449 | +€1,228 | +100.5% |
| Accrued charges and deferred income | 492/3 | - | €1,119 | +€1,119 | |
| Remuneration, social security and pensions | 62 | €7,182 | €1,257 | -€5,926 | -82.5% |
| Other operating charges | 640/8 | - | €808 | +€808 | |
| Gross operating margin | 9900 | €16,909 | -€687 | -€17,596 | |
| Operating profit (loss) | 9901 | €9,727 | -€2,751 | -€12,478 | |
| Financial income | 75/76B | €48 | €208 | +€161 | +338.2% |
| Recurring financial income | 75 | €48 | €208 | +€161 | +338.2% |
| Financial charges | 65/66B | €55 | €142 | +€87 | +157.4% |
| Recurring financial charges | 65 | €55 | €142 | +€87 | +157.4% |
| Profit (loss) for the period before taxes | 9903 | €9,719 | -€2,686 | -€12,405 | |
| Income taxes | 67/77 | €2,595 | €0 | -€2,595 | -100.0% |
| Profit (loss) for the period | 9904 | €7,124 | -€2,686 | -€9,810 | |
| Profit (loss) for the period to be appropriated | 9905 | €7,124 | -€2,686 | -€9,810 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2023 and 31 December 2024. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 September 2026 via checked.be.